{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:56Z","timestamp":1793835896437,"version":"4.6.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Hormone therapy in transgender people might be associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate whether the risk of CVD is increased in transgender people compared with people of the same birth sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and methods<\/jats:title>\n                    <jats:p>PubMed, Cochrane, Embase, and Google Scholar were searched until July 2022. Studies evaluating cardiovascular events in transgender women or men were included. Primary outcomes were stroke, myocardial infarction (MI), and venous thromboembolism (VTE). The risk for transgender women versus cisgender men and for transgender men versus cisgender women was analysed through random-effects meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two studies involving 19 893 transgender women, 14 840 transgender men, 371 547 cisgender men, and 434 700 cisgender women were included. The meta-analysis included 10 studies (79% of transgender women and 76% of transgender men). In transgender women, incidence of stroke was 1.8%, which is 1.3 (95% confidence interval [CI], 1.0-1.8) times higher than in cisgender men. Incidence of MI was 1.2%, with a pooled relative risk of 1.0 (95% CI, 0.8-1.2). Venous thromboembolism incidence was 1.6%, which is 2.2 (95% CI, 1.1-4.5) times higher. Stroke occurred in 0.8% of transgender men, which is 1.3 (95% CI, 1.0-1.6) times higher compared with cisgender women. Incidence of MI was 0.6%, with a pooled relative risk of 1.7 (95% CI, 0.8-3.6). For VTE, this was 0.7%, being 1.4 (95% CI, 1.0-2.0) times higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Transgender people have a 40% higher risk of CVD compared with cisgender people of the same birth sex. This emphasizes the importance of cardiovascular risk management. Future studies should assess the potential influence of socio-economic and lifestyle factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvad170","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T07:58:23Z","timestamp":1706687903000},"page":"S13-S24","source":"Crossref","is-referenced-by-count":109,"title":["Cardiovascular disease in transgender people: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-0261","authenticated-orcid":false,"given":"Lieve Mees","family":"van Zijverden","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-0065","authenticated-orcid":false,"given":"Chantal Maria","family":"Wiepjes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-9076","authenticated-orcid":false,"given":"Jeske Joanna Katarina","family":"van Diemen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Thijs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-5617","authenticated-orcid":false,"given":"Martin","family":"den Heijer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"},{"name":"Centre of Expertise on Gender Dysphoria, Amsterdam UMC Location Vrije Universiteit Amsterdam , De Boelelaan 1117 , Amsterdam 1081HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"4","key":"2024022907465826500_lvad170-B1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jsxm.2018.01.016","article-title":"The Amsterdam cohort of gender dysphoria study (1972-2015): trends in prevalence, treatment, and regrets","volume":"15","author":"Wiepjes","year":"2018","journal-title":"J Sex Med"},{"issue":"Suppl 1","key":"2024022907465826500_lvad170-B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"11","key":"2024022907465826500_lvad170-B3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2016.5451","article-title":"Lifelong gender gap in risk of incident myocardial infarction: the tromso study","volume":"176","author":"Albrektsen","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2024022907465826500_lvad170-B4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/ATVBAHA.116.307301","article-title":"Sex hormones and sex chromosomes cause sex differences in the development of cardiovascular diseases","volume":"37","author":"Arnold","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2024022907465826500_lvad170-B5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/01.STR.32.5.1104","article-title":"Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women","volume":"32","author":"Matthews","year":"2001","journal-title":"Stroke"},{"issue":"1","key":"2024022907465826500_lvad170-B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0008-6363(00)00005-5","article-title":"The roles of gender, the menopause and hormone replacement on cardiovascular function","volume":"46","author":"Hayward","year":"2000","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2024022907465826500_lvad170-B7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.19.3.713","article-title":"Menopausal status and distensibility of the common carotid artery","volume":"19","author":"Westendorp","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"2024022907465826500_lvad170-B8","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"2024022907465826500_lvad170-B9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-85-4-447","article-title":"Menopause and risk of cardiovascular disease: the Framingham study","volume":"85","author":"Kannel","year":"1976","journal-title":"Ann Intern Med"},{"issue":"1","key":"2024022907465826500_lvad170-B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13293-017-0152-8","article-title":"The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy","volume":"8","author":"Iorga","year":"2017","journal-title":"Biol Sex Differ"},{"issue":"1","key":"2024022907465826500_lvad170-B11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/AOG.0b013e31827a08c8","article-title":"Lessons learned from the Women's health initiative trials of menopausal hormone therapy","volume":"121","author":"Rossouw","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2024022907465826500_lvad170-B12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"2024022907465826500_lvad170-B13","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1210\/jc.2018-02138","article-title":"Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen","volume":"104","author":"van Velzen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024022907465826500_lvad170-B14","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/HYPERTENSIONAHA.120.16839","article-title":"Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults","volume":"77","author":"Banks","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"2024022907465826500_lvad170-B15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacl.2022.11.010","article-title":"Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy","volume":"17","author":"Leemaqz","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2024022907465826500_lvad170-B16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jsxm.2021.01.185","article-title":"Does gender-affirming hormonal treatment affect 30-year cardiovascular risk in transgender persons? A two-year prospective European study (ENIGI)","volume":"18","author":"Cocchetti","year":"2021","journal-title":"J Sex Med"},{"issue":"6","key":"2024022907465826500_lvad170-B17","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","article-title":"Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults","volume":"74","author":"Connelly","year":"2019","journal-title":"Hypertension"},{"issue":"11","key":"2024022907465826500_lvad170-B18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"2024022907465826500_lvad170-B19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1530\/EJE-14-0011","article-title":"Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern","volume":"170","author":"Gooren","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"8990","key":"2024022907465826500_lvad170-B20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"2024022907465826500_lvad170-B21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/jth.15256","article-title":"Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen","volume":"19","author":"Scheres","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2024022907465826500_lvad170-B22","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1210\/jc.2011-0367","article-title":"Socioeconomic trajectories affect mortality in Klinefelter syndrome","volume":"96","author":"Bojesen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024022907465826500_lvad170-B23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1530\/EC-21-0119","article-title":"Socioeconomic status in Danish transgender persons: a nationwide register-based cohort study","volume":"10","author":"Glintborg","year":"2021","journal-title":"Endocr Connect"},{"issue":"10042","key":"2024022907465826500_lvad170-B24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(16)00683-8","article-title":"Transgender people: health at the margins of society","volume":"388","author":"Winter","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2024022907465826500_lvad170-B25","first-page":"37","article-title":"Gender dysphoria: prejudice from childhood to adulthood, but no impact on inflammation. A cross-sectional controlled study","volume":"43","author":"Real","year":"2021","journal-title":"Trends Psychiatry Psychother"},{"issue":"2","key":"2024022907465826500_lvad170-B26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/01612840.2021.1961330","article-title":"Health impact of stigma, discrimination, prejudice, and bias experienced by transgender people: a systematic review of quantitative studies","volume":"43","author":"Drabish","year":"2022","journal-title":"Issues Ment Health Nurs"},{"issue":"6","key":"2024022907465826500_lvad170-B27","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1161\/CIR.0000000000001003","article-title":"Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association","volume":"144","author":"Streed","year":"2021","journal-title":"Circulation"},{"key":"2024022907465826500_lvad170-B28","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2024022907465826500_lvad170-B29","first-page":"41","article-title":"Meta-analysis with zero-event studies: a comparative study with application to COVID-19 data","volume":"8","author":"Wei","year":"2021","journal-title":"Mil Med Res"},{"issue":"9","key":"2024022907465826500_lvad170-B30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"2024022907465826500_lvad170-B31","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2024022907465826500_lvad170-B32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"3","key":"2024022907465826500_lvad170-B33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"11","key":"2024022907465826500_lvad170-B34","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jsxm.2016.09.001","article-title":"Incidence of venous thromboembolism in transgender women receiving oral estradiol","volume":"13","author":"Arnold","year":"2016","journal-title":"J Sex Med"},{"issue":"10","key":"2024022907465826500_lvad170-B35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","article-title":"Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria","volume":"9","author":"de Blok","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024022907465826500_lvad170-B36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10865-019-00102-8","article-title":"Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS","volume":"43","author":"Caceres","year":"2020","journal-title":"J Behav Med"},{"issue":"10","key":"2024022907465826500_lvad170-B37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist","volume":"113","author":"Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"2024022907465826500_lvad170-B38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.13821","article-title":"Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration","volume":"89","author":"Gava","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2024022907465826500_lvad170-B39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Internl Med"},{"issue":"3","key":"2024022907465826500_lvad170-B40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/EJE-22-0306","article-title":"Cardiovascular risk in Danish transgender persons: a matched historical cohort study","volume":"187","author":"Glintborg","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024022907465826500_lvad170-B41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13293-020-00332-5","article-title":"A community-based study of demographics, medical and psychiatric conditions, and gender dysphoria\/incongruence treatment in transgender\/gender diverse individuals","volume":"11","author":"James","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"15","key":"2024022907465826500_lvad170-B42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/eurjpc\/zwac133","article-title":"Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy","volume":"29","author":"Karalexi","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2024022907465826500_lvad170-B43","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211051546","article-title":"Effects of testosterone treatment on transgender males: a single-institution study","volume":"9","author":"Korpaisarn","year":"2021","journal-title":"SAGE Open Med"},{"issue":"1","key":"2024022907465826500_lvad170-B44","first-page":"42","article-title":"Prevalence and predictors of cardiovascular disease and risk factors in transgender persons in the United States","volume":"21","author":"Malhotra","year":"2022","journal-title":"Crit Pathw Cardiol"},{"issue":"4","key":"2024022907465826500_lvad170-B45","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-023549","article-title":"Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy","volume":"147","author":"Mullins","year":"2021","journal-title":"Pediatrics"},{"key":"2024022907465826500_lvad170-B46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2021.09.005","article-title":"Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone","volume":"207","author":"Oakes","year":"2021","journal-title":"Thromb Res"},{"issue":"4","key":"2024022907465826500_lvad170-B47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy","volume":"93","author":"Ott","year":"2010","journal-title":"Fertil Steril"},{"issue":"6","key":"2024022907465826500_lvad170-B48","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amepre.2021.05.019","article-title":"Cardiovascular disease in a population-based sample of transgender and cisgender adults","volume":"61","author":"Poteat","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"2024022907465826500_lvad170-B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/trgh.2019.0061","article-title":"An observational study of hypertension and thromboembolism among transgender patients using gender-affirming hormone therapy","volume":"5","author":"Pyra","year":"2020","journal-title":"Transgender Health"},{"issue":"12","key":"2024022907465826500_lvad170-B50","doi-asserted-by":"crossref","first-page":"e018121","DOI":"10.1136\/bmjopen-2017-018121","article-title":"Cohort profile: study of transition, outcomes and gender (STRONG) to assess health status of transgender people","volume":"7","author":"Quinn","year":"2017","journal-title":"BMJ Open"},{"issue":"5","key":"2024022907465826500_lvad170-B51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1018704630036","article-title":"A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients","volume":"27","author":"Schlatterer","year":"1998","journal-title":"Arch Sex Behav"},{"issue":"10","key":"2024022907465826500_lvad170-B52","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J Sex Med"},{"issue":"4","key":"2024022907465826500_lvad170-B53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-13-0493","article-title":"Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study","volume":"169","author":"Wierckx","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024022907465826500_lvad170-B54","doi-asserted-by":"crossref","first-page":"e16885","DOI":"10.1371\/journal.pone.0016885","article-title":"Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden","volume":"6","author":"Dhejne","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"2024022907465826500_lvad170-B55","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1530\/EJE-14-0527","article-title":"Epidemiology of hormonal contraceptives-related venous thromboembolism","volume":"171","author":"Hugon-Rodin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2024022907465826500_lvad170-B56","first-page":"446","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"issue":"9","key":"2024022907465826500_lvad170-B57","doi-asserted-by":"crossref","first-page":"e004500","DOI":"10.1161\/CIRCOUTCOMES.117.004500","article-title":"Psychological distress and risk of myocardial infarction and stroke in the 45 and up study","volume":"11","author":"Jackson","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2024022907465826500_lvad170-B58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12874-022-01694-7","article-title":"Sample size calculation for prevalence studies using Scalex and ScalaR calculators","volume":"22","author":"Naing","year":"2022","journal-title":"BMC Med Res Methodol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/2\/S13\/56740881\/lvad170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/2\/S13\/56740881\/lvad170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:47:55Z","timestamp":1709174875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/2\/S13\/7596368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad170","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,2,1]]}}}